TxCell to update on recent achievements in cellular therapy market at leading forthcoming investor conferences

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, announces today that Stephane Boissel, CEO, TxCell and other senior management will either attend, present to, and meet investors at a number of leading forthcoming investor conferences.

The conferences give TxCell the opportunity to continue to update investors about the potential and opportunities in the cellular therapy market as well as achievements by TxCell following the reorganization and refocusing of the Company conducted throughout 2015.

TxCell’s recent strategic decisions enable TxCell to open a totally new chapter and so present its ambitious new targets, including this of bringing at least three new products to clinical development within five years. These decisions include firstly, to outsource manufacturing activities to concentrate its effort and resources on research and development, including process development. Secondly TxCell decided to reacquire the full rights to its lead product Ovasave(R) and lastly, to accelerate its efforts on its second product platform of CAR-Treg cells.

The next investor conferences that TxCell will participate in include:

  • European Midcap Event, 9th edition, Frankfurt, Germany - February 17, 2016
  • 2016 Credit Suisse London Healthcare Conference, London, UK - March 1-2, 2016
  • BioCapital Europe, Amsterdam, The Netherlands – March 9, 2016
  • 4th Alliance for Regenerative Medicine Annual Cell and Gene Investor Day, New York, USA – March 22, 2016

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches